Clinical Trial Detail

NCT ID NCT01984242
Title A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements no
Sponsors Hoffmann-La Roche
Indications

renal cell carcinoma

Therapies

Atezolizumab

Sunitinib

Atezolizumab + Bevacizumab + Capecitabine

Age Groups: adult senior

No variant requirements are available.